Hutch News

Hutch News

Stories tagged 'Aude Chapuis'

Immunotherapy shows promise in preventing leukemia relapse

Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years

Dec. 5, 2016 | By Susan Keown / Fred Hutch News Service

For patients with high-risk acute myeloid leukemia, relapse after bone marrow transplant signals a low chance of survival. But results from a small trial of genetically engineered immune cells show promise for keeping these patients out of danger: Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.

View story >


Investing in the future

Five researchers get surprise grants through new President’s Young Investigator Awards

June 27, 2016 | By Sabin Russell / Fred Hutch News Service

This spring, five “young investigators” working at the Seattle cancer research center ― or soon to join it ― received entirely unexpected notes from Fred Hutch president and director Dr. Gary Gilliland. And the notes carried a bigger surprise. Each scientist had been awarded a $100,000 grant for “unrestricted” research in their laboratories.

View story >


Dr. Aude Chapuis

10 questions about life outside the lab for the Fred Hutch immunotherapy researcher

June 15, 2016 | By Bill Briggs / Fred Hutch News Service

Immunotherapy researcher Dr. Aude Chapuis moved from Switzerland to the United States in 2003. Get to know the avid skier and parent to a Play-Doh chef.

View story >


New clues to treating deadly skin cancer

Small clinical trial finds two forms of immunotherapy may be better than one for treating metastatic melanoma

June 6, 2016 | By Rachel Tompa / Fred Hutch News Service

Matthew Flood, a retired EMT from the Tacoma Fire Department, is one of 10 patients with metastatic melanoma treated with an experimental combination of immunotherapies between 2011 and 2013. In a study published today in the Journal of Clinical Oncology, the research team described the small clinical trial and how the patients have fared in the years following their treatment. Flood is now in complete remission five years after receiving the combo immunotherapy.

View story >


Tailoring immune cells to target leukemia

Promising early trial results show engineered immune cells may help buffer against cancer relapse after bone marrow transplantation

April 21, 2016 | By Sabrina Richards / Fred Hutch News Service

Dr. Phil Greenberg’s team at Fred Hutch has developed methods to genetically modify T cells, a type of immune cell, to specifically seek out cancer cells while they ignore healthy cells. On Wednesday, he presented results of an early-stage trial at the American Association for Cancer Research annual conference in New Orleans that appear to show promise in preventing disease relapse after blood stem cell transplantation.

View story >


6 questions in cancer immunotherapy

From cancer vaccines to engineered T cells, experts weigh in on the big unknowns

March 18, 2016 | by Susan Keown / Fred Hutch News Service

Fred Hutch immunotherapy experts share their perspectives on a few of the big questions in cancer immunotherapy research — and the steps that they and their colleagues are taking to answer them as quickly as they can.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.